Nichols David Wayne 4/A
4/A · Magenta Therapeutics, Inc. · Filed May 17, 2021
Insider Transaction Report
Form 4/AAmended
Nichols David Wayne
Chief Technical Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-04-19+175,000→ 175,000 totalExercise: $10.50Exp: 2031-04-18→ Common Stock (175,000 underlying)
Footnotes (2)
- [F1]This option shall vest and become exerciseable over four years, with 25% of this option vesting on April 19, 2022, and the remainder vesting in 36 equal monthly installments thereafter.
- [F2]This amendment has been filed to revise the vesting terms of Mr. Nichols' stock option, which were reported incorrectly on Mr. Nichols' prior Form 4. The corrected vesting schedule is included in Footnote 1 above.